Market Overview:

Veterinary oncology refers to specialized veterinary medicine and care provided to companion animals and non-production animals who suffer from cancer. Veterinary oncology helps in the diagnosis, staging, and grading of tumors as well as treatment through chemotherapy, radiation therapy, surgery, immunotherapy, and other protocols. Veterinary oncology aims to control, eliminate, or minimize clinical signs of cancer while preserving or improving the pet's quality of life.

Key Takeaways

The Global Veterinary Oncology Market Size is expected to witness high growth, exhibiting CAGR of 10.% over the forecast period, due to increasing pet adoption and rising pet care expenditure.

The North America region is expected to dominate the market owing to growing pet healthcare expenditure and increasing number of vet care facilities in the region. According to one estimate, the US spends over $30 billion annually on vet care.

Key players operating in the veterinary oncology market are Zoetis Inc., Elanco, AB Science, Boehringer Ingelheim International GmbH, Zenoaq, VetDC, Morphogenesis, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., AdvaVet, Inc., and Rhizen Pharmaceutical SA. Zoetis dominated the market with over 20% revenue share in 2023 due to its robust oncology portfolio. However, the market is expected to witness entry of new players focusing on novel targeted therapies.

Read More - https://www.articledistrict.com/the-growth-of-veterinary-oncology-market/